| A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors
| [0013]
|
| Lapatinib for Advanced or Metastatic Breast Cancer
| [0015]
|
| Clinical use of crizotinib for the treatment of non-small cell lung cancer
| [0016]
|
| Remington's Pharmaceutical Sciences Handbook
| [0034]
|
| Treatment of Advanced Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology
| [0053]
|
| ALK inhibitors in the treatment of advanced NSCLC
| [0053]
|
| Lapatinib plus capecitabine for HER2-positive advanced breast cancer
| [0053]
|
| Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab
| [0053]
|
| Regorafenib: a review of its use in previously treated patients with progressive metastatic colorectal cancer
| [0053]
|
| Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy
| [0053]
|
| Fasting enhances the response of glioma to chemo- and radiotherapy
| [0053]
|
| Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin
| [0053]
|
| Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy
| [0053]
|
| Toxicity in chemotherapy--when less is more
| [0053]
|
| Fasting and cancer treatment in humans: A case series report
| [0053]
|
| Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression
| [0053]
|
| First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors
| [0053]
|
| Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells
| [0053]
|
| Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications
| [0053]
|
| Short-term calorie and protein restriction provide partial protection from chemotoxicity but do not delay glioma progression
| [0054]
|